Source comparison
Tesamorelin: Peptide Comparison
The table below compares tesamorelin to other growth hormone secretagogues and direct GH replacement in terms of mechanism, fat loss selectivity, and metabolic impact. This comparison clarifies why tesamorelin research review conclusions emphasize visceral fat
This comparison does not assign a generated winner or score.
- The table below compares tesamorelin to other growth hormone secretagogues and direct GH replacement in terms of mechanism, fat loss selectivity, and metabolic impact. This comparison clarifies why tesamorelin research review conclusions emphasize visceral fat specificity rather than generalized weight loss.
- Tesamorelin
- GHRH receptor agonist; stimulates pulsatile endogenous GH release
- 15–18% VAT reduction in 26-week RCTs; no effect on SAT
- Preserved (no significant change from baseline)
- Transient fasting glucose elevation (+4–6 mg/dL); stable A1C
- Gold standard for selective VAT reduction with lowest metabolic disruption; FDA-approved for lipodystrophy
- Sermorelin
- GHRH analogue; shorter half-life than tesamorelin (10–20 min)
- Limited trial data; case reports suggest 8–12% VAT reduction over 12–24 weeks
- Modest increase in lean mass reported in smaller studies
- Minimal glucose impact; lower GH pulse amplitude than tesamorelin
- Effective GH secretagogue but less consistent VAT response due to rapid degradation
- Ipamorelin + CJC-1295
- Ghrelin receptor agonist (ipamorelin) + GHRH analogue (CJC-1295); synergistic GH release
- No published RCT data on VAT-specific reduction; anecdotal reports only
- Increased lean mass in observational studies
- Elevated appetite (ghrelin effect); potential insulin sensitivity reduction
- Popular in research settings but lacks rigorous clinical endpoint data for fat loss
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic; sustained GH and IGF-1 elevation
- Generalized fat loss without VAT selectivity; 3–7% body fat reduction in 12-week studies
- Significant lean mass gain (+2–4 kg)
- Sustained hyperglycemia risk; increased appetite and water retention
- Effective for lean mass but poor choice for selective VAT reduction; metabolic trade-offs
- Exogenous GH (somatropin)
- Direct GH receptor agonist; bypasses pituitary regulation
- 10–15% VAT reduction but also reduces SAT; less selective than tesamorelin
- Substantial lean mass increase
- Insulin resistance, joint pain, edema common at therapeutic doses
- Most potent lipolytic agent but highest side effect burden; loss of physiological feedback
- Tesamorelin's clinical advantage is anatomical selectivity. The 15–18% VAT reduction occurs without corresponding SAT loss or lean mass change, a profile that direct GH administration and ghrelin mimetics do not replicate. This is the reason it remains the only FDA-approved pharmacological treatment specifically indicated for abdominal fat reduction.